JPWO2023076989A5 - - Google Patents

Info

Publication number
JPWO2023076989A5
JPWO2023076989A5 JP2024525063A JP2024525063A JPWO2023076989A5 JP WO2023076989 A5 JPWO2023076989 A5 JP WO2023076989A5 JP 2024525063 A JP2024525063 A JP 2024525063A JP 2024525063 A JP2024525063 A JP 2024525063A JP WO2023076989 A5 JPWO2023076989 A5 JP WO2023076989A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
antigen
binding fragment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540017A (ja
JP2024540017A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078767 external-priority patent/WO2023076989A1/en
Publication of JP2024540017A publication Critical patent/JP2024540017A/ja
Publication of JP2024540017A5 publication Critical patent/JP2024540017A5/ja
Publication of JPWO2023076989A5 publication Critical patent/JPWO2023076989A5/ja
Pending legal-status Critical Current

Links

JP2024525063A 2021-10-29 2022-10-27 抗pd-1抗体と、抗cd30抗体-薬物コンジュゲートとの組合せを用いてがんを処置する方法 Pending JP2024540017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163273411P 2021-10-29 2021-10-29
US63/273,411 2021-10-29
PCT/US2022/078767 WO2023076989A1 (en) 2021-10-29 2022-10-27 Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate

Publications (3)

Publication Number Publication Date
JP2024540017A JP2024540017A (ja) 2024-10-31
JP2024540017A5 JP2024540017A5 (https=) 2025-11-04
JPWO2023076989A5 true JPWO2023076989A5 (https=) 2025-11-04

Family

ID=84370103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525063A Pending JP2024540017A (ja) 2021-10-29 2022-10-27 抗pd-1抗体と、抗cd30抗体-薬物コンジュゲートとの組合せを用いてがんを処置する方法

Country Status (11)

Country Link
US (1) US20250179182A1 (https=)
EP (1) EP4423135A1 (https=)
JP (1) JP2024540017A (https=)
KR (1) KR20240099363A (https=)
CN (1) CN118451108A (https=)
AU (1) AU2022377628A1 (https=)
CA (1) CA3236735A1 (https=)
IL (1) IL312110A (https=)
MX (1) MX2024005080A (https=)
TW (1) TW202333783A (https=)
WO (1) WO2023076989A1 (https=)

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69424687T2 (de) 1993-03-09 2000-09-07 Genzyme Corp., Cambridge Verfahren zur isolierung von proteinen aus milch
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
RS53984B1 (sr) 2003-12-10 2015-10-30 E. R. Squibb & Sons L.L.C. Ip-10 antitela i njihove upotrebe
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
CA3159253A1 (en) 2009-01-09 2010-07-15 Seagen Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
US8446101B2 (en) 2009-07-20 2013-05-21 Gallen Ka Leung Tsui Control switch
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
US10613092B2 (en) 2016-04-01 2020-04-07 Agilent Technologies, Inc. Scoring methods for anti-PD therapy eligibility and compositions for performing same
MA50369A (fr) 2017-10-13 2020-08-19 Seattle Genetics Inc Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament
CA3093731A1 (en) 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor

Similar Documents

Publication Publication Date Title
US20230310595A1 (en) Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
JP2021515017A5 (https=)
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2021523233A5 (https=)
US20240307541A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
JP2021518394A5 (https=)
JP2021523158A5 (https=)
TW202330040A (zh) 抗her2抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
WO2011090005A1 (ja) 大腸癌の治療用医薬および治療方法
JPWO2019173523A5 (https=)
CN115698076A (zh) 用于治疗肿瘤的药物
WO2021182571A1 (ja) 癌の治療及び/又は予防のための医薬品
WO2021182574A1 (ja) 癌の治療及び/又は予防のための医薬品
JPWO2019217455A5 (https=)
JPWO2019183253A5 (https=)
JPWO2023076989A5 (https=)
RU2024114358A (ru) Способы лечения рака комбинацией антитела против pd-1 и конъюгата антитела против cd30-лекарственного средства
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
JPWO2019217457A5 (https=)
JPWO2021090272A5 (https=)
HK40075828B (en) Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
JPWO2021089588A5 (https=)
JPWO2023133388A5 (https=)
JPWO2021173832A5 (https=)